ABSTRACT
Since vaccines against COVID-19 are available, it has been debated if immunosuppressed patients with autoimmune blistering diseases (AIBDs) should be advised to interrupt the immunosuppressive therapy before receiving the vaccine, with consequent risk to experience a flare of disease. In the present study, we measured the neutralizing antibodies production after anti-SARS-CoV-2 vaccination in patients with AIBDs on immunosuppressive treatment, compared to healthy controls. Our results give strength to the hypothesis that these patients do not need to discontinue their therapy to produce effective levels of neutralizing antibodies, in other words to achieve successful protection.
Subject(s)
Autoimmune Diseases , COVID-19 , Humans , COVID-19 Vaccines , Immunosuppressive Agents , Immunosuppression Therapy , Antibodies, Neutralizing , Blister , Vaccination , Antibodies, ViralABSTRACT
The purpose is to verify whether patients with Long Covid-19 symptoms can recover Functional Capabilities and Endurance reaching the normotype subjects' level. The study is a before-after trial comparing the affected sample with baseline normotype data. The study was carried out at the private clinic "Move Different" near Aosta Italy. The clinic has an agreement with public health for a project for patients with Long Covid-19 symptoms. About 60 subjects (mean age 62+-3) healed from Covid-19 Virus with more than one day of hospitalization, older than 60 years old were included. They were divided into two clusters: Low Performance Patients (LPP) and Medium Performance Patients (MPP), decided by the Medical Equipe. The program consisted of 10 sessions of 1h, divided into 2/3 treatments per week;based on the use of Virtual Reality and Augmented Reality through a Digital Mirror. Tests were performed before and after the intervention. Increase in meters covered in the 6 Minutes Walking Test (MPP increases 56+- 65 meters, LPP increases 99+-74 meters). Wilcoxon test was performed between pre and post 6MWT for both of populations (pvalue < 0.005, pvalue < 0.005). After the treatment, results are close to normative data of Perera et al, 2006, Geriatrics. The improvement of both groups is statistically significantly difference;data support that especially the medium-functional group achieves the similar level of normotype subjects. A future randomized control trial aimed at testing whether improvement of this method over a traditional one is suggested. The authors declared no potential conflicts of interest with respect to the research authorship and/or publication of this poster.
ABSTRACT
The purpose is to verify whether patients with Long Covid-19 symptoms can recover Functional Capabilities and Endurance reaching the normotype subjects' level. The study is a before-after trial comparing the affected sample with baseline normotype data. The study was carried out at the private clinic "Move Different" near Aosta Italy. The clinic has an agreement with public health for a project for patients with Long Covid-19 symptoms. About 60 subjects (mean age 62+-3) healed from Covid-19 Virus with more than one day of hospitalization, older than 60 years old were included. They were divided into two clusters: Low Performance Patients (LPP) and Medium Performance Patients (MPP), decided by the Medical Equipe. The program consisted of 10 sessions of 1h, divided into 2/3 treatments per week;based on the use of Virtual Reality and Augmented Reality through a Digital Mirror. Tests were performed before and after the intervention. Increase in meters covered in the 6 Minutes Walking Test (MPP increases 56+- 65 meters, LPP increases 99+-74 meters). Wilcoxon test was performed between pre and post 6MWT for both of populations (pvalue < 0.005, pvalue < 0.005). After the treatment, results are close to normative data of Perera et al, 2006, Geriatrics. The improvement of both groups is statistically significantly difference;data support that especially the medium-functional group achieves the similar level of normotype subjects. A future randomized control trial aimed at testing whether improvement of this method over a traditional one is suggested. The authors declared no potential conflicts of interest with respect to the research authorship and/or publication of this poster.
ABSTRACT
During the COVID-19 pandemic, various cutaneous manifestations have been described as associated with SARS-CoV2 infection. It is debated if skin lesions could represent a diagnostic or prognostic indicator. Specifically, it is unclear whether skin lesions may be used to perform an early diagnosis and/or to predict worse outcomes. In this review, we described the cutaneous signs so far reported as COVID-19-related and discussed their incidence, clinico-pathological features, and diagnostic and prognostic value.